ProQR Therapeutics N.V. (PRQR)

USD 2.57

(-12.59%)

Market Cap (In USD)

265.23 Million

Revenue (In USD)

6.51 Million

Net Income (In USD)

-28.11 Million

Avg. Volume

113.15 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.61-4.62
PE
-
EPS
-
Beta Value
0.253
ISIN
NL0010872495
CUSIP
N71542109
CIK
1612940
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Daniel Anton de Boer
Employee Count
-
Website
https://www.proqr.com
Ipo Date
2014-09-18
Details
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.